Thursday November 29

West Coast Day 2

Emerging & Reemerging Vaccine Targets

Therapeutic Immunotherapy Approaches

Vaccine Technology & Manufacture

Vaccine Development

A novel approach to developing single dose and safe vaccines for emerging infectious diseases

  • In vivo production of VLPs allows them to be more readily recognized by the immune system
  • Safety and durability of vaccines demonstrated in HIV clinical trials
  • Platform can be applied to multiple vaccine targets including; Ebola, Zika and Lassa
  • Differs from other platforms as there is no need for adjuvants and is thermally and genetically stable
Delivery, Bioprocessing & Manufacturing

Expanding Vaccine Effectiveness with Needle-Free Delivery

  • Commercially available Needle-free delivery systems
  • Established clinical efficacy with commercial vaccines
  • Helping Nucleic Acid based vaccines toward licensure

Morning Networking Break & Poster Session

Interactive Roundtables

Choose one of our roundtables for interactive discussions with like-minded peers tackling the similar challenges in:

Challenges for next generation adjuvants


Considerations for successful cancer immunotherapy in aged hosts


Development of predictive biomarkers to determine optimal combinations in precision immunotherapy


How can we improve speed, delivery and cost of next generation cancer vaccines?


Legal considerations for partnering with government bodies, pharma and biotechs


Oncolytic virus strategies; Development personalized oncolytic viral vaccines


What are the next steps when immunotherapy trials fail after receiving accelerated approval?


What are we doing to target potential responders or enrich for potential responders in immuno-oncology?


Networking Lunch & Poster Session

Antibodies for Infectious / Autoimmune Diseases

Antibodies in Cancer

Manufacturing Immunotherapies

Delivery, Bioprocessing & Manufacturing

A DNA vaccine platform to rapidly produce countermeasures against emerging viral threats

  • Describe a highly scalable manufacturing process for the rapid production of DNA-based vaccines for emerging infectious diseases
  • Discuss the stability profile of our DNA-based product
  • Offer a real-life example of a rapid response to an infectious disease – Zika
Vaccine Development

Development of trispecific antibodies for the treatment of HIV and potential for application to other infectious diseases

  • Background on broadly neutralizing antibodies to HIV addressing potency and breadth of coverage
  • Potential for combinations of antibodies to provide optimum coverage for therapy or prevention of HIV infection
  • Pre-clinical development and testing of a trispecific anti-HIV antibody molecule
  • Update on clinical development and testing of a trispecific anti-HIV antibody molecule

Bispecific Technology for Multiple Avenues of T-cell Activation

  • Checkpoint bispecifics to improve therapeutic index: PD1 x CTLA4
  • Triple checkpoint blockade: LAG3 x CTLA4 bispecific plus anti-PD1
  • Checkpoint plus costim.: PD1 x ICOS
  • Potency-tuned IL15 for prolonged T cell stimulation
Delivery, Bioprocessing & Manufacturing

Meeting the demand: Why continued innovation in immunotherapy manufacturing is crucial

Dr Kim Nelson, Senior Director for Strategic Consulting, C.R.B.

Afternoon Networking Break

Antibody Technology & Delivery

Vaccine Development

Harnessing Natural Immunity to Create Breakthrough Therapies for Infectious Diseases

  • These antibodies are isolated from individuals with natural immunity against pathogens.
  • Antibody sequences are derived from unmodified heavy and light chain human B lymphocyte sequences that have undergone ontogeny and selection inside a human body.
  • Antibodies derived as a result of a human immune response are expected to exhibit high affinity, ideal safety and pharmacokinetics.
  • XBiotech’s discovery and production technologies help bring these novel therapeutics from bench to bedside in a relatively short timeframe
Delivery, Bioprocessing & Manufacturing

Advances in technology and ongoing challenges in the development of next generation antibody therapeutics

  • Overview of status of bispecific research – advantages of bispecific therapies vs two monotherapies
  • Alternative scaffolds for bispecific antibodies
  • Manufacturing strategies and challenges – production, engineering and stability
Vaccine Development

Development of a broadly neutralizing monoclonal antibody with extended half-life technology for the prevention of RSV in all infants

  • Overview of early discovery work
  • Updates from 2 completed clinical trials
  • New work on International Network for Optimal Resistance Monitoring (INFORM) RSV in collaboration with ReSViNET

Biologic and clinical activity of first in class ICOS agonist antibody in combination with checkpoint inhibitors

  • Preclinical rationale for development of JTX-2011, an ICOS agonist
  • Rationale for combinations with PD-1 inhibitors, CTLA-4 inhibitors, and vaccines
  • Clinical and biomarker data for JTX-2011 in patients with advanced solid tumors that supports further development
Vaccine Development

Immune Dampening and Refocusing for deriving novel biologics for difficult and unmet infectious disease and oncology applications

  • Addressing the problem of evolved immunodominance in antigenic structures
  • What is deceptive Imprinting and how does it work?
    • e.g. what is its evolutionary benefit?
  • What are the immuno-chemical-physical characteristics that drive it?
    • e.g. how can these be identified today and tomorrow?
  • What processes and technologies are available to overcome this evolved pathogen survival strategy?
    • Review Immune refocusing technology
Delivery, Bioprocessing & Manufacturing

Rapid discovery of rare B-cells and manufacturing of mAbs with MabIGX technology

  • Application of nano-culture arrays to comprehensively screen the B-cell repertoire from convalescent patients for rare, functionally optimized B-cells
  • Immortalization and stabilization of selected B-cell using engineered fusion partner cell line to obviate the need for recombinant mAb expression from conventional mAb production cell lines

Chair’s closing remarks of day two followed by offsite networking drinks reception at Stone Brewery, Liberty Station

last published: 22/Nov/18 11:45 GMT



Sign Up for Event Updates

Contact us

To sponsor or exhibit contact:
Oliver Breed
+44 (0)207 092 1156

To speak:
Lauren Sheppard
+44 (0)207 092 1211